



Symbol	Name	Synonyms	Organism
<b>CDKN1C</b>	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	BWCR, BWS, Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, HGNC:1154, KIP2, p57, P57, p57KIP2, WBS	Homo sapiens


UniProt P49918  
 IntAct P49918  
 OMIM 130650, 600856  
 NCBI Gene 1028  
 NCBI RefSeq NP\_000067  
 NCBI RefSeq NM\_000076  
 NCBI UniGene 1028  
 NCBI Accession AAB05896, P49918

Homologues of CDKN1C ... **new**

Interaction information for this gene  ...




Enhanced PubMed/Google query ... **new**




WARNING: Please keep in mind that gene detection is done automatically and can exhibit a certain error. Read more about synonym ambiguity and the iHOP confidence value .




Find in this Page 




Analysis of CDKN1C  in Beckwith Wiedemann syndrome.  




New p57KIP2 mutations in Beckwith-Wiedemann syndrome.  

Low frequency of p57KIP2  mutation in Beckwith-Wiedemann syndrome.  



CDKN1C  expression in Beckwith-Wiedemann syndrome patients with allele imbalance.  




Functional analysis of the p57KIP2  gene mutation in Beckwith-Wiedemann syndrome.  




Here we describe p57KIP2  mutations in patients with Beckwith-Wiedemann syndrome.  




An imprinted gene p57KIP2  is mutated in Beckwith-Wiedemann syndrome [see comments].  




Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C  mutations.  



Is p57KIP2 mutation a common mechanism for Beckwith-Wiedemann syndrome or somatic overgrowth? [letter].  

Coding mutations in p57KIP2  are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors.  

The gene encoding p57KIP2  is located at 11p15.5, a region implicated in both sporadic cancers and Beckwith-Wiedemann syndrome (BWS).  

In this study we have examined 32 patients with Beckwith Wiedemann Syndrome (BWS) for mutations affecting the CDKN1C  gene, including seven cases of familial BWS.  

The gene encoding p57KIP2  is located at 11p15.5 (ref. 2), a region implicated in both sporadic cancers and Beckwith-Wiedemann syndrome, a cancer-predisposing syndrome, making it a tumour-suppressor candidate.  

In contrast, p57KIP2 expression in cytotrophoblast and villous mesenchyme was absent or markedly decreased in 58 of 59 complete hydatidiform moles.  

We explored the utility of p57KIP2 as a diagnostic marker in hydatidiform mole, a

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	195274	BWCR or BWS or Cyclin-dependent adj kinase adj inhibitor adj 1C or Cyclin-dependent adj kinase adj inhibitor adj p57 or "HGNC:1154" or KIP2 or p57 or P57 or p57KIP2 or WBS	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:34
L2	274959	cancer\$ or tumor\$ or neoplas\$ or malig\$ or hyperprol\$ or tumour\$	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:35
L3	12576	L1 and L2	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:35
L4	18886480	@py<="2002"	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:36
L5	1373	L3 and L4	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:36
L6	17735292	@py<="2001"	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:36
L7	976	L6 and L3	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:37
L8	4925	435/4.ccls.	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:38
L9	2438	L8 and L6	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:38
L10	9	L8 and L7	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:42
L11	114	"CDK inhibitory protein"	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:42
L12	10	L11 and L5	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:44
L13	22	"cyclin-dependent kinase inhibitor 1C"	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:49
L14	1	L13 and L6	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:46

L15	22	L13 and L1	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:50
L16	22	L15 and L2	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:52
L17	1	L13 and L4	US-PGPUB; USPAT; DERWENT	OR	ON	2006/01/13 14:51

US 20060003391 A1	US-PGPUB	20060105	75	
Reagents and methods for use in cancer diagnosis, classification and therapy				
435/7.23				Ring; Brian Z. et al.
US 20050287532 A9	US-PGPUB	20051229	69	
Methods for monitoring drug activities in vivo				435/6
435/7.21				Burczynski, Michael E. et al.
US 20050095592 A1	US-PGPUB	20050505	82	
Identification of ovarian cancer tumor markers and therapeutic targets				
435/6	435/7.23			Jazaeri, Amir A et al.
US 20050059012 A1	US-PGPUB	20050317	42	
Diagnosis of ZD1839 resistant tumors				435/6
435/183; 435/320.1; 435/325; 435/69.1; 530/388.26; 536/23.2				
Afar, Daniel et al.				
US 20040241653 A1	US-PGPUB	20041202	678	
Methods for identifying marker genes for cancer				435/6
435/7.23				Feinstein, Elena et al.
US 20040175743 A1	US-PGPUB	20040909	69	
Methods for monitoring drug activities in vivo				435/6
435/7.21				Burczynski, Michael E. et al.
US 20030138793 A1	US-PGPUB	20030724	34	
Molecular signatures of commonly fatal carcinomas				435/6
435/287.2; 536/24.3				Su, Andrew I. et al.
US 20030086934 A1	US-PGPUB	20030508	88	Basal
cell markers in breast cancer and uses thereof				424/185.1
435/6; 435/7.23				Botstein, David et al.
US 20060003338 A1	US-PGPUB	20060105	25	System
and methods for the management and treatment of vascular graft disease				
435/6 435/287.2; 435/7.1				Deng; David Xing-Fei et al.
US 20050272055 A1	US-PGPUB	20051208	154	
Method of treating lethal shock induced by toxic agents and diagnosing exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes				435/6 Das, Rina et al.
US 20050209181 A1	US-PGPUB	20050922	122	
Compositions and methods for diagnosing and treating mental disorders				514/44 435/6; 514/220; 514/259.41; 514/469
Akil, Huda et al.				
US 20050158756 A1	US-PGPUB	20050721	15	
Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy				435/6 702/20
Hare, Joshua M. et al.				
US 20050137805 A1	US-PGPUB	20050623	255	Gene
expression profiles that identify genetically elite ungulate mammals				
702/19 435/6; 702/20				Lewin, Harris A. et al.

US 20050100933 A1	US-PGPUB	20050512	23	Breast
cancer survival and recurrence		435/6 435/91.2		
Erlander, Mark G. et al.				
US 20050032186 A1	US-PGPUB	20050210	97	
Regulatory zinc finger proteins		435/199		
435/320.1; 435/325; 435/6; 435/69.1; 536/23.2				Kim,
Jin-Soo et al.				
US 20040259948 A1	US-PGPUB	20041223	32	
Reciprocal regulation of inflammation and lipid metabolism by				
liver X receptors	514/560			Tontonoz,
Peter et al.				
US 20040191783 A1	US-PGPUB	20040930	23	Low
density micro-array analysis in human breast cancer		435/6		
435/287.2	Leclercq, Guy et al.			
US 20040076955 A1	US-PGPUB	20040422	253	
Methods of diagnosis of bladder cancer, compositions and methods				
of screening for modulators of bladder cancer		435/6		
435/320.1; 435/325; 435/69.1; 530/350; 536/23.5				Mack,
David H. et al.				
US 20040053277 A1	US-PGPUB	20040318	43	Strong
gene sets for glioma classification		435/6 435/7.23		
Zhang, Wei et al.				
US 20040038292 A1	US-PGPUB	20040226	621	Wound
healing biomarkers	435/7.1	435/226; 435/320.1; 435/325;		
435/69.1; 536/23.2	Burslem, Martyn Frank et al.			
US 20030082511 A1	US-PGPUB	20030501	78	
Identification of modulatory molecules using inducible promoters				
435/4 435/6	Brown, Steven J. et al.			
WO 200136632 A	A2, A3DERWENT	20010525	519	Novel
alternative splicing variants e.g. variant of angiotensin converting enzyme				
(ACEV), useful in identifying candidate compounds capable of binding to				
the variant and to detect anti-variant antibodies				
AZAR, I et al.				